Polymorphism in methylenetetrahydrofolate reductase gene: Its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis

被引:34
作者
Lim, PS [1 ]
Hung, WR
Wei, YH
机构
[1] Natl Yang Ming Univ, Dept Biochem, Sch Life Sci, Taipei 112, Taiwan
[2] Kuang Tien Gen Hosp, Dept Nephrol, Taipei, Taiwan
[3] Natl Yang Ming Univ, Ctr Cellular & Mol Biol, Taipei 112, Taiwan
关键词
hyperhomocysteinemia; methylenetetrahydrofolate reductase gene; carotid atherosclerosis; hemodialysis;
D O I
10.1159/000045922
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The methylenetetrahydrofolate reductase (MTH FR) gene polymorphism has been shown to be associated with cardiovascular disease in healthy subjects as well as in patients with end-stage renal disease (ESRD). In this study, we examined the allelic frequency and genotype distribution of the MTHFR gene in 151 Chinese ESRD patients receiving hemodialysis and 135 healthy controls. In addition, we investigated the relationship between the MTHFR gene polymorphism and the plasma homocysteine (Hcy) level as well as the intima-media thickness of common carotid artery (CC-IMT) in these patients. The allelic frequency of the MTHFR gene with the C677T mutation in ESRD patients was 24.5% and that in healthy controls was 23%. Mean plasma Hey level of the ESRD patients (23.1 +/- 7.4 mu mol/l) was significantly higher than that of the controls (10.1 +/- 5.0 mu mol/l), but did not correlate with vitamin B-6 and vitamin B-12 status. Moreover, the extent of hyperhomocysteinemia was genetically affected by the C677T mutation of the MTHFR gene. The plasma Hey levels for the patients with the CC, CT and TT genotypes of the MTHFR gene were 22.3 +/- 6.8, 22.8 +/- 7.3, and 28.3 +/- 2.8 mu mol/l, respectively. In addition, we found that the patients bearing the TT genotype had the highest CC-IMT (0.93 +/- 0.07 mm), whereas the lowest values (0.79 +/- 0.13 mm) were observed in those who had the CC genotype. One-way ANOVA showed that the CC-IMT in the patients with the TT genotype was significantly greater than that of the patients with the CC genotype (p < 0.05). Moreover, the mean CC-IMT of the patients carrying either TT or CT genotype of the MTHFR gene was significantly higher th an that of the patients bearing the CC genotype (0.86 <plus/minus> 0.14 vs. 0.79 +/- 0.13 mm, p = 0.002). Multiple regression analysis, in which the change in CC-IMT was used as the dependent variables, identified age, smoking, the MTHFR genotype (CC = 0, CT = 1, TT = 2) and diabetes mellitus as the independent variables significantly associated with the increase of CC-IMT (p < 0.001). These risk factors jointly explained 43.9% of the CC-IMT variation and age explained most of the variation (R-2 = 0.34). We conclude that both the TT genotype and the T allele of the MTHFR gene are associated with the increase of CC-IMT in hemodialysis patients. The C677T mutation of the MTHFR gene may be an independent risk factor that predicts the development of carotid atherosclerosis in ESRD patients. Copyright <(c)> 2001 S. Karger AG, Basel.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 46 条
[1]   DETERMINATION OF FREE AND TOTAL HOMOCYSTEINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
ARAKI, A ;
SAKO, Y .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 :43-52
[2]  
ARNADOTTIR M, 1993, CLIN NEPHROL, V40, P236
[3]  
BACHMANN J, 1995, J AM SOC NEPHROL, V6, P121
[4]   Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Nadeau, MR ;
Sutherland, P ;
Chan, J ;
Rozen, R ;
Yoburn, D ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ATHEROSCLEROSIS, 1996, 123 (1-2) :193-202
[5]   HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[6]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[7]   Homocysteine and short-term risk of myocardial infarction and stroke in the elderly -: The Rotterdam study [J].
Bots, ML ;
Launer, LJ ;
Lindemans, J ;
Hoes, AW ;
Hofman, A ;
Witteman, JCM ;
Koudstaal, PJ ;
Grobbee, DE .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) :38-44
[8]   Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease -: The result of a meta-analysis [J].
Brattström, L ;
Wilcken, DEL ;
Öhrvik, J ;
Brudin, L .
CIRCULATION, 1998, 98 (23) :2520-2526
[9]  
CHAUVEAU P, 1993, KIDNEY INT, V43, pS72
[10]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155